Business Description
Day One Biopharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US23954D1090
Total Employee Number:
178Description
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 157.94 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 18.8 | |||||
Beneish M-Score | -1.78 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.7 | |||||
3-Year EPS without NRI Growth Rate | 18.4 | |||||
3-Year FCF Growth Rate | 14.7 | |||||
3-Year Book Growth Rate | -1.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.27 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.16 | |||||
9-Day RSI | 81.3 | |||||
14-Day RSI | 80.32 | |||||
3-1 Month Momentum % | 78.91 | |||||
6-1 Month Momentum % | 185.45 | |||||
12-1 Month Momentum % | 170.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.02 | |||||
Quick Ratio | 7.91 | |||||
Cash Ratio | 7.29 | |||||
Days Inventory | 113.75 | |||||
Days Sales Outstanding | 43.86 | |||||
Days Payable | 86.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.9 | |||||
Shareholder Yield % | -0.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.12 | |||||
Operating Margin % | -80.76 | |||||
Net Margin % | -67.85 | |||||
EBITDA Margin % | -78.37 | |||||
FCF Margin % | -68.01 | |||||
OCF Margin % | -65.59 | |||||
ROE % | -22.98 | |||||
ROA % | -20.19 | |||||
ROIC % | -455.4 | |||||
3-Year ROIIC % | 90.21 | |||||
ROC (Joel Greenblatt) % | -2688 | |||||
ROCE % | -26.97 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 14.06 | |||||
PB Ratio | 5.03 | |||||
Price-to-Tangible-Book | 5.24 | |||||
EV-to-EBIT | -13.98 | |||||
EV-to-EBITDA | -14.41 | |||||
EV-to-Revenue | 11.29 | |||||
EV-to-Forward-Revenue | 7.59 | |||||
EV-to-FCF | -16.61 | |||||
| Price-to-Net-Current-Asset-Value | 5.3 | |||||
| Price-to-Net-Cash | 5.91 | |||||
Earnings Yield (Greenblatt) % | -7.15 | |||||
FCF Yield % | -4.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DAWN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Day One Biopharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 158.182 | ||
| EPS (TTM) ($) | -1.04 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 107.38 | ||
| 14-Day RSI | 80.32 | ||
| 14-Day ATR ($) | 0.144803 | ||
| 20-Day SMA ($) | 21.4675 | ||
| 12-1 Month Momentum % | 170.63 | ||
| 52-Week Range ($) | 5.635 - 21.53 | ||
| Shares Outstanding (Mil) | 103.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Day One Biopharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Day One Biopharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 179 days | ||
| Annual report for 2026 | 2027-02-24 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 178 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 67 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 66 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 21.53 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 21.53 (+0.00%) | ||
| General meeting for 2026 | 2026-06-02 10:00 | 21.53 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 21.53 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 21.53 (+0.00%) |
Show
Entries
Day One Biopharmaceuticals Inc Frequently Asked Questions
What is Day One Biopharmaceuticals Inc(DAWN)'s stock price today?
The current price of DAWN is $21.53. The 52 week high of DAWN is $21.53 and 52 week low is $5.64.
When is next earnings date of Day One Biopharmaceuticals Inc(DAWN)?
The next earnings date of Day One Biopharmaceuticals Inc(DAWN) is 2026-11-04 Est..
Does Day One Biopharmaceuticals Inc(DAWN) pay dividends? If so, how much?
Day One Biopharmaceuticals Inc(DAWN) does not pay dividend.
Guru Commentaries on NAS:DAWN
2025 Q1
What the manager wrote
Day One Biopharmaceuticals Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Their lead drug Ojemda is used to treat certain types of brain tumors (gliomas) in patients six months and older. The launch has been promising with 280 patients on therapy in December. Despite its early success, there are concerns about the addressable market and prescribing patterns. We decided to sell out of the position, which declined by -35% for the time it was held in the quarter.
2025 Q1
What the manager wrote
Day One Biopharmaceuticals Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Their lead drug Ojemda is used to treat certain types of brain tumors (gliomas) in patients six months and older. The launch has been promising with 280 patients on therapy in December. Despite its early success, there are concerns about the addressable market and prescribing patterns. We decided to sell out of the position, which declined by -35% for the time it was held in the quarter.
Press Release
Articles on Day One Biopharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers